Researchers at Johns Hopkins has concluded that metastasis-free survival appeared to independently predictor of overall survival (OS) in men with recurrent prostate cancer who underwent androgen deprivation therapy (ADT) after developing metastases.
Men with biochemically recurrent prostate cancer (PSA only) tend to survive for long periods so the FDA gold standard for clinical trial endpoint of OS has proven to be a difficult endpoint to reach in clinical trials.
Consequently, researchers have long indicated the need for intermediate endpoints to help conduct these types of trials in a shorter time.
Emmanuel S. Antonarakis, MBBCh, of the Prostate Cancer Research Program at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, and colleagues conducted retrospective analysis of 450 men with recurrent prostate cancer.
All of the men had a prostatectomy at a single institution between 1981 and 2010. Additionally, androgen deprivation therapy (ADT) was deferred until after the men developed metastases.
Of the 450 men in the subject pool 140 of them developed metastases during the time being surveyed.
They found the following:
1- Median metastasis-free surviva